Skip to main content
OpenTrials
Completed

NCT Number: NCT05138978

Metagenomic and Metatranscriptomic Analysis of Clinical Plaque Samples

The objective of this study is to determine the metagenomic and metatranscriptomic analysis of clinical samples.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

King's College London Dental Institute, UK

London, United Kingdom

About this study

This study is a blinded, non-randomized, crossover design. Subjects who meet the inclusion/exclusion criteria will be enrolled in the study. Following enrollment, subjects will be asked to use a washout dentifrice (#200000035883/001/000) for a minimum of 1 week. Fasting plaque will be collected at Baseline and then again at a duplicate baseline collection up to 1 week after the baseline collection. Subjects will be assigned a new dentifrice (#200000035883/001/000) to use for 12 weeks. After 12 weeks' use, fasting plaque will be collected. There will be a duplicate plaque collection up to 1 week after 12 week collection. Subjects will be given a new dentifrice (#200000040228/001/000) to use for the next 24 weeks. After 24 weeks' use, fasting plaque will be collected, and there will be a duplicate plaque collection up to 1 week after this collection.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and/or female subjects 16 years and above
  • Minimum of 20 natural uncrowned teeth (excluding third molars) must be present
  • Caries active subjects will have at least 3 active caries lesions (ICDAS score 1 - 3). Caries free control subjects will either have ICDAS score 0 or ICDAS score of 1 - 3 where the lesion is inactive.
  • Available throughout entire study
  • Willing to use only assigned products for oral hygiene throughout the duration of the study
  • Must give written informed consent
  • Must be in good general health

Exclusion criteria

  • Unwilling or unable to sign an Informed Consent Form
  • Advanced periodontal disease
  • Medical condition which requires premedication prior to dental visits/procedures
  • Diseases of the soft or hard oral tissues
  • Orthodontic appliances that interfere with clinical assessments
  • Impaired salivary function
  • Current use of drugs that can affect salivary flow
  • Use antibiotics 3 months prior to or during this study
  • Use of any arginine containing oral care products such as Colgate Sensitive Pro-Relief and Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer dentifrices 3 months prior to or during this study
  • Pregnant or breastfeeding
  • Participate in another clinical study 1 week prior to the start of the washout period or during the study period
  • Use of tobacco products
  • Allergic to common dentifrice ingredients
  • Allergic to amino acids
  • Immune compromised individuals (HIV, AIDS, immuno-suppressive drug therapy)

Treatment and study plan

Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer

Drug

Toothpaste

Colgate Cavity Protection

Drug

Toothpaste

Primary outcomes

  1. DNA (metagenomic) sequences

    Time frame: 38 weeks

    The primary outcome is to collect plaque following each treatment and to assess DNA

  2. RNA (metatranscriptomic) sequences

    Time frame: 38 weeks

    The primary outcome is to collect plaque following each treatment and to assess RNA

Sponsors and collaborators

Lead sponsor

Colgate Palmolive

Industry

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Dec 1, 2021
Registry last updated
Dec 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.